Pune, July 19, 2019 (GLOBE NEWSWIRE) -- The global Ophthalmic Disease Therapeutics Market is projected to reach US$ 47,831.3 Mn by 2026. This growth is attributable to increased...
Amgen (AMGN) and collaboration partner Allergan (AGN) announce the commercial availability of MVASI (bevacizumab-awwb), a biosimilar to Roche's (RHHBY) Ava
The FDA accepts for review Allergan's (AGN) marketing application for Bimatoprost Sustained-Release ((SR)) for reducing intraocular pressure in patients wi
This week marked the start of the second-quarter earnings season for the pharma space with J&J (NYSE:JNJ) and Novartis (NYSE:NVS) releasing their results. Meanwhile, the...
Allergan plc (NYSE:AGN) announced that the FDA has accepted the new drug application (“NDA”) for its investigational biodegradable implant candidate, Bimatoprost SR....
Wall Street expects a year-over-year decline in earnings on lower revenues when Allergan (NYSE:AGN) reports results for the quarter ended June 2019. While this widely-known...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Buy||Strong Buy||BUY||Strong Sell||BUY|
|Summary||Strong Buy||Strong Buy||Buy||Neutral||Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Belt Hold Bullish||1D||Current|
|Deliberation Bearish||1W||2||Jun 30, 2019|
|Three Outside Up||1W||3||Jun 23, 2019|
|Bullish Engulfing||1W||4||Jun 16, 2019|
Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. The US General Medicine segment includes sales relating to branded products within the United States that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women's Health, Anti-Infectives and Diversified Brands. The International segment includes sales relating to products sold outside the United States.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.